Masaryk University's nuclease drug development program for cancer treatment that targets DNA damage response was licensed to Artios Pharma. The firm also gets the option to commercialize the product.
Czech Republic university's cancer drug licensed to Artios
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.